William Blair research analyst Matt Larew’s note to investors on 10x Genomics was cited by Investor’s Business Daily.
In the piece profiling CEO Serge Saxonov’s outlook for the biotech company, the publication shared Larew’s perspective that “[William Blair’s equity research team] continue[s] to believe that 2023 could be an inflection year for 10x…and new guidance represents a 14%-18% top-line outlook with 40%-plus spatial growth and low- to mid-teens single-cell growth.”